Literature DB >> 10150699

How to identify the cause of antibiotic-associated diarrhea.

J G Bartlett1.   

Abstract

Most cases of antibiotic-associated diarrhea are due to Clostridium difficile or are of enigmatic etiology. The antibiotics most often implicated are clindamycin, ampicillin or amoxicillin, and the cephalosporins. Clinical signs of antibiotic-associated diarrhea may be limited to watery stools; however, evidence of colitis (fever, cramps, leukocytosis, fecal leukocytes) suggests C. difficile infection. The tissue culture assay for C. difficile toxin remains the gold standard for diagnosis, but the enzyme immunoassay is a practical and reasonably accurate alternative. Anatomic changes, such as pseudomembranes, can be confirmed with endoscopy, but such evaluation is not required for diagnosis of C. difficile-associated pseudomembranous colitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10150699

Source DB:  PubMed          Journal:  J Crit Illn        ISSN: 1040-0257


  3 in total

1.  Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?

Authors:  Savio Reddymasu; Ankur Sheth; Daniel E Banks
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-04-19       Impact factor: 3.944

2.  A prospective cross sectional study of detection of Clostridium difficile toxin in patients with antibiotic associated diarrhoea.

Authors:  Arun Sachu; Kavitha Dinesh; Ismail Siyad; Anil Kumar; Anu Vasudevan; Shamsul Karim
Journal:  Iran J Microbiol       Date:  2018-02

3.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.